Generic medications: another variable in the treatment of illnesses

Blakesley V.A. (2005) Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate . AAPS J 7: E42—E46

Borgheini G. (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs . Clin Ther 25: 1578—1592

CanadaDrugs.com (2006) Brand vs. Generic. Available at www.canadadrugs.com (accessed 21 November 2006)

Canadian Generics Pharmaceutical Association ( 2006) Brand Name Drugs vs. Generic Drugs: What's the Difference? Available at http://www.canadiangenerics.ca/en/resource/BrandvsGeneric-What%27stheDifference.pdf (accessed 21 November 2006)

Canadian Health Protection Branch (HPB) (1992 ) Drugs Directorate Guidelines Conduct and analysis of bioavailability and bioequivalence studies — Part A: oral dosage formulations used for systemic effects. Page 6, http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/fedstate_sujetsjeun_e.html

Committee for Proprietary Medicinal Products (CPMP) (1991) Working Party on on Efficacy of Medicinal Products. Note for guidance: investigation of bioavailablility and bioequivalence . Pharmacol Toxicol 68: 75—76

Food and Drug Administration (FDA) — Centre for Drug Evaluation and Research (CDER) (2000) Guidance for Industry — Levothyroxine sodium tablets — in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. Available at http://www.fda.gov/default.htm. (accessed 3 January 2007)

Food and Drug Administration (FDA), Centre for Drug Evaluation and Research (CDER) (1992) Guidance for Industry: statistical procedures for bioequivalence studies using a standard two-treatment crossover design, http://www.fda.gov/Cder/guidance/3616fnl.pdf

Gervasoni M. , Pirola R. , Bareggi S.R. , Tonello C. , Nisoli E. , Vialba L. (2004) The bioequivalence and therapeutic efficacy . Clin Ther 26: 801—802

Meyer M.C. (2001) United States Food and Drug Administration requirements for approval of generic drug products . J Clin Psychiatry 62 Suppl 5: 4—9

Office of the Auditor General of Canada (2006 ) Allocating funds to Regulatory Programs — Health Canada . November 2006 Report. Availableatwww.oag-bvg.gc.cachapter8,8.23 (accessed 11 November 2006 )

Opelz G. (2001) CTS Collaborative Transplant Study, Newsletter 1: 2001. Available at http://www.ctstransplant.org (accessed 5 January 2007)

Qazi Y.A. , Forrest A. , Tornatore K. , Venuto R.C. (2006) The clinical impact of 1:1 conversion from neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function . Clin Transplant 20: 313—317

Rosenbaum D.H. , Rowan A.J. , Tuchman L. , French J.A. (1994) Comparative bioavailability of a generic phenytoin and Dilantin . Epilepsia 35: 656—660

Smith J.C. , Tarocco G. , Merazzi F. , Salzmann U. (2006) Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Curr Med Res Opin 22: 709—720

Taber D.J. , Baillie G.M. , Ashcraft E.E. , Rogers J. , Lin A. , Afzal F. , Baliga P. , Rajagopalan P.R. , Chavin K.D. (2005) Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 80: 1633—1635

The European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use (2001) Note for Guidance on the Investigation of Bioavailability and Bioequivalence . Page 5, http://www.emea.europa.eu/pdfs/human/ewp/140198en.pdf

Van Ameringen M , Mancini C. , Patterson B. , Bennett M. (2007) Symptom relapse following switch from Celexa to generic citalopram . J Psychopharm 21: 472—476